Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of LAYLA in Osteoarthritis
NCT01768468Phase 4Completed
- Sponsor
- PMG Pharma
- Start
- Oct 2012
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of PG201 in knee osteoarthritis (OA) (2 arms), sponsored by PMG Pharma. Primary endpoint: Change in 100mm Pain Visual Analog Scale at 8 weeks. Started Oct 2012; status: completed.
02
Drugs
PG201
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01768468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01768468.